All In Biotech

Drug Trial Radar · NCT07400965

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Dec 5, 2025

Primary completion

Sep 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Glaukos CorporationIndustry
Sponsor type
Industry
First posted
Feb 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-masked, placebo-controlled, dose-ranging, parallel-group, multi-center study designed to evaluate the safety and efficacy of GLK-321 in patients with Demodex blepharitis.

Conditions

  • Demodex Blepharitis

Interventions

  • GLK-321 low dose BIDDrug

    Twice daily administration of low dose GLK-321 to both eyes

  • GLK-321 mid dose BIDDrug

    Twice daily administration of mid dose GLK-321 to both eyes

  • GLK-321 high dose BIDDrug

    Twice daily administration of high dose GLK-321 to both eyes

  • GLK-321 high dose QDDrug

    Once daily administration of high dose GLK-321 to both eyes

  • Placebo BIDDrug

    Twice daily administration of placebo to both eyes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of study eyes with elimination of collarettesTime frame: 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Glaukos Clinical Study Site

    Newport Beach, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.